Evidence map›Paper›PMID 30655820›Full record

ArticleOncology letters2019

miR-34a inhibits esophageal squamous cell carcinoma progression via regulation of FOXM1.

Haibo Zhou, Li Yang, Xinhua Xu, Mingqian Lu, Rong Guo, Daojun Li, Qiao Huang, Yang Liu, Glenn Deng, Yalin Xu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Haibo ZhouInstitute of Oncology, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Li YangDepartment of Thyroid and Breast, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Xinhua XuInstitute of Oncology, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Mingqian LuInstitute of Oncology, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Rong GuoInstitute of Oncology, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Daojun LiInstitute of Oncology, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Qiao HuangInstitute of Oncology, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Yang LiuInstitute of Oncology, The First College of Clinical Medical Science, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang, Hubei 443000, P.R. China.
Glenn DengSchool of Medicine, Stanford University, Stanford, CA 94305, USA.
Yalin XuDepartment of Clinical Laboratory, Chibi Pu Spinning Hospital, Chibi, Hubei 437321, P.R. China.
China Three Gorges University · CNYichang Central People's Hospital · CNStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Downregulation of microRNA-34a (miR-34a) has frequently been observed in esophageal squamous cell carcinoma (ESCC). However, the underlying role and molecular mechanism of miR-34a in ESCC remains largely unknown. In the current study, it was demonstrated that miR-34a was downregulated and forkhead box M1 (FOXM1), a target gene of miR-34a, was upregulated in ESCC tumor tissues. Overexpression of miR-34a decreased FOXM1 mRNA and protein expression in the ESCC cell lines tested (TE-1 and TE-8). Inhibition of miR-34a increased FOXM1 mRNA and protein levels in human esophageal epithelial cells (HEEC). In addition, miR-34a mimics reduced the relative luciferase activity of ESCC cells transfected with FOXM1 3'UTR-WT, but not FOXM1 3'UTR-Mut. The CCK8 assay and scratch wound healing assay showed that overexpression of miR-34a induced inhibition of cell proliferation and cell migration. Additionally, transfection with miR-34a mimics reduced the expression of key genes involved in cell migration (MMP2 and MMP9) in ESCC cells. Thus, the present data demonstrated that miR-34a suppressed ESCC progression by directly targeting FOXM1.

Indexed as

esophageal squamous cell carcinomaFOXM1miR-34a

Identifiers

PMID30655820
PMCPMC6312991
OpenAlexW2895860876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.